Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

NCT00006345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Drug/Agent Toxicity by Tissue/Organ
Lymphoma

Interventions

BIOLOGICAL: denileukin diftitox
DRUG: dexamethasone

Sponsor

Ligand Pharmaceuticals